Humacyte Inc (HUMA): Street Finally Waking Up

Currently, there are 119.84M common shares owned by the public and among those 104.37M shares have been available to trade.

The company’s stock has a 5-day price change of -10.92% and -28.93% over the past three months. HUMA shares are trading 33.63% year to date (YTD), with the 12-month market performance up to 22.82% higher. It has a 12-month low price of $2.48 and touched a high of $9.97 over the same period. HUMA has an average intraday trading volume of 3.02 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -12.60%, -23.33%, and -29.99% respectively.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Institutional ownership of Humacyte Inc (NASDAQ: HUMA) shares accounts for 27.90% of the company’s 119.84M shares outstanding.

It has a market capitalization of $488.30M and a beta (3y monthly) value of 1.38. The earnings-per-share (ttm) stands at -$1.34. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.98% over the week and 8.26% over the month.

Analysts forecast that Humacyte Inc (HUMA) will achieve an EPS of -0.25 for the current quarter, -0.25 for the next quarter and -0.86 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.31 while analysts give the company a high EPS estimate of -0.31. Comparatively, EPS for the current quarter was -0.26 a year ago. Earnings per share for the fiscal year are expected to decrease by -26.40%, and 36.24% over the next financial year.

Looking at the support for the HUMA, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 11, 2023, with the firm’s price target at $6. Piper Sandler coverage for the Humacyte Inc (HUMA) stock in a research note released on August 14, 2023 offered a Neutral rating with a price target of $3.50. Cantor Fitzgerald was of a view on June 22, 2023 that the stock is Overweight, while Piper Sandler gave the stock Underweight rating on May 16, 2022, issuing a price target of $10- $4. Cowen on their part issued Outperform rating on October 29, 2021.

Most Popular

Related Posts